Truist analyst Gregory Renza initiated coverage of Abivax (ABVX) with a Buy rating and $140 price target Following a second-half re-rate from phase 3 induction data in ulcerative colitis, investors are focused on obefazimod’s increasing value proposition and set-up for key phase 3 UC maintenance data in Q2 of 2026 and phase 2b induction topline in Crohn’s disease coming the second half of 2026, the analyst tells investors in a research note. Obefazimod represents an unusual mechanism of action, which the firm views as being backed by preclinical and clinical evidence indicating broad immunological effects, Truist added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
- Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating
- Abivax initiated with an Outperform at Wolfe Research
- Abivax announces patient-reported outcomes from ABTECT trial
- Abivax initiated with an Overweight at Barclays